Quantitative comparison of erythropoietin receptor levels in the epithelial versus endothelial fractions of primary breast tumors.

Publication Type:

Journal Article


Anticancer research, Volume 31, Issue 4, p.1189-95 (2011)


2011, Adenocarcinoma, Mucinous, Adult, Aged, Aged, 80 and over, Breast Neoplasms, Carcinoma, Ductal, Breast, Carcinoma, Lobular, Endothelium, Vascular, Epithelial Cells, Erythropoietin, Female, Humans, Janus Kinase 2, Lasers, microdissection, Middle Aged, Public Health Sciences Division, Receptors, Erythropoietin, Reverse Transcriptase Polymerase Chain Reaction, RNA, Messenger, Stromal Cells


Erythropoietin (EPO) was shown to reduce tumor survival in recent trials, however, its mechanisms of action are unclear. Efforts to measure tumor EPO receptor (EPOR) are limited by the promiscuity of EPOR antibodies, and concerns as to whether EPOR mRNA measurements are confounded by heterogeneity of tumor vasculature, a known EPOR source.